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Abstract
Background: Limited data exists regarding healthcare utilization, medical expenses, and prognosis of pulmonary
hypertension (PH) according to the World Health Organization (WHO) classification. We aimed to investigate
mortality risk, healthcare utilization and medical expenditure in patients with PH across the five diagnostic
subgroups.
Methods: We identified 2185 patients with PH, defined as peak tricuspid regurgitation velocity > 3.4 m/sec, among
the consecutive patients referred for echocardiography between 2009 and 2015. Using diagnostic codes, medical
records, and echocardiographic findings, the enrolled patients were classified according to the five subgroups by
WHO classification. Healthcare utilization, costs, and all-cause mortality were assessed.
Results: Diagnostic subgroups of PH demonstrated significantly different clinical features. During a median of 32.4
months (interquartile range, 16.2–57.8), 749 patients (34.3%) died. Mortality risk was the lowest in group II (left heart
disease) and highest in group III (chronic lung disease). The etiologies of pulmonary arterial hypertension (PAH) had
significant influence on the mortality risk in group I, showing the worst prognosis in PAH associated with
connective tissue disease. Medical expenditure and healthcare utilization were different between the PH subgroups:
groups II and V had more hospitalizations and medical expenses than other groups. Regardless of PH subgroups,
the severity of PH was associated with higher mortality risk, more healthcare utilization and medical expenditure.
Conclusions: Significant differences in clinical features and prognostic profiles between PH subgroups reflect the
differences in pathophysiology and clinical consequences. Our findings highlight the importance of comprehensive
understanding of PH according to the etiology and its severity.
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Background
Pulmonary hypertension (PH) is a frequently encoun-
tered clinical condition. Several cohort studies reported
that the prevalence of PH is higher than previously rec-
ognized: ranges from 2.6% among general population,
[1] to 9.1% among those who were referred for echocar-
diography [2]. In addition, the presence of PH is associ-
ated with higher risk of cardiovascular events.
PH is categorized into 5 diagnostic subgroups of dif-
ferent etiology: pulmonary arterial hypertension (PAH;
group I), PH due to left-sided heart disease (PH-LHD;
group II), PH due to lung disease or hypoxemia (PH-
Lung; group III), chronic thromboembolic PH (CTEPH;
group IV), and PH of miscellaneous causes (PH-Miscel-
laneous) [3]. Until now, there have been several studies
that compared the overall incidence of PH according to
the WHO classification [2, 4, 5]. But most of these stud-
ies limited their scope to idiopathic or associated PAH,
but not other subgroups [6]. Moreover, there has been
no study that compared healthcare utilization and
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medical expenditure according to the WHO classifica-
tion of PH.
In this study, we aimed to describe the clinical charac-
teristics of the five diagnostic subgroups of PH according
to the WHO classification, to compare the risk of mor-
tality of PH patients between the subgroups, and to in-
vestigate whether the healthcare utilization and medical
costs are different between the five subgroups.
Methods
Study population and WHO classification
The study was carried out according to the principles of
the Declaration of Helsinki and approved by the Clinical
Research Institute of Seoul National University Bundang
Hospital.
We retrospectively identified a total of 272,688 echo-
cardiography exams performed at Seoul National Uni-
versity Bundang Hospital and Seoul National University
Hospital between 2009 and 2015. We used a peak tricus-
pid regurgitant (TR) flow velocity > 3.4 m/sec for echo-
cardiographic diagnosis of PH, [3] and identified 2843
patients with PH. Then, study population was classified
according to the five diagnostic subgroups of PH, using
a 2-step process: at first, we categorized the total study
population using the comorbidities that were identified
by diagnostic codes according to the International Statis-
tical Classification of Diseases and Related Health Prob-
lems, 10th revision (ICD-10) (Additional file 1), and by
reviewing detailed descriptions in the electronic medical
record. Echocardiographic findings of grade II or III dia-
stolic dysfunction or septal E/e’ ratio > 15 were also used
for the categorization of group II PH (PH-LHD) [7].
When a patient has diagnostic codes, echocardiographic
findings, or other characteristics satisfying more than 1
subgroup of PH, the patient’s electronic medical record
was reviewed for differentiation. Two reviewers inde-
pendently assessed the study population according to
WHO classification, and cases of disagreement within
the reviewers were resolved through discussion.
Patients with uncertain classification and those with
prior diagnosis of malignancy were excluded (n = 653),
in order to avoid any impacts from malignancy on the
medical expenditure for diagnosis and management, as
well as on the prognosis. Finally, a total of 2185 patients
were included in the analysis.
Echocardiography
All echocardiography images were obtained in accord-
ance with current guidelines [8]. LV end-systolic and
end-diastolic volumes and LV ejection fraction (LVEF)
were calculated using the biplane Simpson method. Left
atrial (LA) volume was calculated by the biplane area-
length method [8]. Pulmonary artery systolic pressure
(PASP) was estimated by summing the peak systolic
trans-tricuspid pressure gradient calculated from peak
velocity of TR and right atrial pressure (RAP) estimated
by diameter and inspiratory collapsibility of inferior vena
cava (IVC): the RAP was estimated as 3 mmHg in pa-
tients with IVC diameter < 2.1 cm that collapses > 50%
with sniffing, 8 mmHg in those with IVC diameter > 2.1
cm that collapses > 50% and in those with IVC diam-
eter < 2.1 cm that collapses < 50%, and 15mmHg in
those with IVC diameter > 2.1 cm that collapses < 50%
[3]. Severity of PH was estimated using the median
PASP value of total study population (62 mmHg) or ar-
bitrary cutoff values of PASP (60 and 70mmHg).
Study outcomes
All-cause mortality during follow-up was assessed until
January 2017. For the confirmation of death, we used
the database from the Korean Ministry of Security and
Public Administration. Healthcare utilization and med-
ical costs of each patient were assessed from July 2009
to December 2016, and were compared between the
subgroups of PH. The number of outpatient department
(OPD) visits, number of hospitalizations, and total dur-
ation of hospitalizations were assessed. Expenditure for
medication, diagnostic testing, and total costs including
medication, diagnostic testing, therapeutic measures,
and hospital stay were compiled using reimbursement
database of the National Health Insurance program.
Medical costs were assessed in Korean Won (KRW), and
were translated into US dollars ($USD) using a currency
exchange rate of 1123 KRW/$USD. In order to avoid the
potential influence from the hospitalizations and related
medical costs that have been intensively occurred early
after enrollment, patients with follow-up duration < 6
months were excluded from the analysis for healthcare
utilization and medical costs.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation (SD) or median with interquartile ranges (IQR;
Q1–Q3); categorical variables are expressed as percent-
ages. Differences in continuous variables were assessed by
Student’s t-test, and categorical variables by Chi-square
test or Fisher’s exact test. Cox proportional hazard regres-
sion model with backward selection method were used to
compare times to the death. Adjusted hazard ratios (HRs)
for all-cause mortality were calculated across the PH sub-
groups. Univariable markers with P values < 0.100 entered
multivariable analysis. All statistical analyses were per-
formed using SPSS 20.0 (IBM Corp., NY, USA).
Results
Baseline characteristics
Table 1 shows baseline characteristics of the study popu-
lation according to the WHO classification of PH. The
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Table 1 Baseline characteristics
Total study
population








(n = 2185) (n = 333) (n = 1189) (n = 335) (n = 102) (n = 226)
Age (years) 67.7 ± 14.9 56.5 ± 17.6 70.0 ± 13.6 72.5 ± 10.6 68.4 ± 14.8 64.4 ± 14.4
Female sex 1123 (51.4%) 227 (68.2%) 611 (51.4%) 110 (32.8%) 71 (69.6%) 104 (46.0%)
BMI (kg/m2) 22.9 ± 3.9 22.6 ± 4.5 23.1 ± 3.7 21.5 ± 3.9 24.9 ± 3.8 22.5 ± 3.5
Comorbidities
Hypertension 638 (29.2%) 83 (24.9%) 389 (32.7%) 66 (19.7%) 27 (26.5%) 73 (32.3%)
Diabetes mellitus 611 (28.0%) 45 (13.5%) 385 (32.4%) 63 (18.8%) 17 (16.7%) 101 (44.7%)
Dyslipidemia 288 (13.2%) 26 (7.8%) 200 (16.8%) 25 (7.5%) 13 (12.7%) 24 (10.6%)
CKD 556 (25.4%) 37 (11.1%) 270 (22.7%) 27 (8.1%) 5 (4.9%) 217 (96.0%)
Chronic hepatitis 307 (14.1%) 18 (5.4%) 202 (17.0%) 58 (17.3%) 10 (9.8%) 19 (8.4%)
Laboratory findings
Hemoglobin (g/dL) 11.8 ± 2.4 12.7 ± 2.8 11.7 ± 2.2 12.6 ± 2.4 12.1 ± 2.4 9.9 ± 1.9
Total cholesterol (mg/
dL)
154.9 ± 42.8 154.0 ± 41.6 155.5 ± 42.3 150.8 ± 41.6 172.2 ± 48.9 150.8 ± 44.2
Triglyceride (mg/dL) 108.5 ± 66.6 111.7 ± 58.8 106.4 ± 61.6 99.6 ± 52.1 170.6 ± 149.3 102.0 ± 51.8
HDL-cholesterol (mg/
dL)
45.0 ± 14.4 46.2 ± 15.0 44.4 ± 13.9 48.1 ± 17.2 44.9 ± 15.1 44.5 ± 13.2
LDL-cholesterol (mg/dL) 91.7 ± 33.3 95.9 ± 31.6 90.6 ± 33.0 87.3 ± 27.4 110.5 ± 38.7 91.1 ± 37.8
BUN (mg/dL) 26.8 ± 19.9 18.1 ± 11.5 27.4 ± 18.8 19.3 ± 11.8 17.9 ± 7.8 51.2 ± 26.8
Creatinine (mg/dL) 1.9 ± 2.6 1.1 ± 1.4 1.8 ± 2.1 1.0 ± 07 0.9 ± 0.7 5.9 ± 4.0
GFR (mL/min/1.73m2) 80.6 ± 55.7 107.6 ± 56.7 75.2 ± 51.0 105.2 ± 53.5 108.2 ± 41.3 22.4 ± 24.7
HbA1c (%) 6.5 ± 1.2 6.4 ± 1.2 6.5 ± 1.2 6.4 ± 0.9 6.5 ± 1.2 6.6 ± 1.4
Echocardiographic findings
LVEDD (mm) 51.0 ± 10.0 45.4 ± 8.5 54.2 ± 9.7 45.3 ± 8.2 44.9 ± 8.3 53.4 ± 7.9
LVESD (mm) 35.6 ± 11.0 29.6 ± 8.5 39.0 ± 11.1 30.1 ± 8.6 30.1 ± 8.5 37.3 ± 9.4
LVEDV (mL) 111.4 ± 61.7 86.1 ± 46.3 120.2 ± 62.5 83.1 ± 47.4 75.7 ± 39.6 81.9 ± 57.8
LVESV (mL) 63.6 ± 50.4 41.5 ± 35.0 71.0 ± 52.0 42.5 ± 36.3 36.7 ± 31.6 81.9 ± 57.8
LVEF (%) 52.5 ± 15.0 60.8 ± 8.4 47.7 ± 16.3 58.3 ± 11.0 61.4 ± 8.6 52.4 ± 12.7
LVMI (g/m2) 121.8 ± 45.0 101.6 ± 42.2 131.6 ± 44.5 102.2 ± 39.7 98.3 ± 41.5 131.7 ± 37.8
LA dimension (mm) 46.6 ± 12.1 41.9 ± 9.4 50.2 ± 12.3 39.2 ± 10.9 39.2 ± 9.3 48.2 ± 7.8
LAVI (mL/m2) 71.9 ± 54.3 56.5 ± 36.8 78.1 ± 59.4 55.0 ± 36.9 51.0 ± 34.1 73.6 ± 40.3
Mitral inflow
E velocity (m/sec) 1.04 ± 0.51 0.80 ± 0.38 1.20 ± 0.53 0.76 ± 0.38 0.70 ± 0.41 1.09 ± 0.35
A velocity (m/sec) 0.92 ± 5.40 0.74 ± 0.37 1.05 ± 7.89 0.84 ± 0.28 0.78 ± 0.24 0.85 ± 0.33
E/A ratio 1.52 ± 2.55 1.11 ± 0.60 1.85 ± 1.25 1.27 ± 5.62 0.90 ± 0.65 1.49 ± 0.87
Deceleration time
(msec)
183.3 ± 92.0 188.7 ± 65.1 182.2 ± 103.6 186.0 ± 93.4 200.6 ± 73.0 169.7 ± 64.0
Mitral annular TDI
e’ velocity (cm/sec) 5.66 ± 2.18 6.06 ± 2.33 5.46 ± 2.15 5.97 ± 2.30 5.62 ± 1.80 5.66 ± 1.90
a’ velocity (cm/sec) 7.77 ± 3.39 8.46 ± 3.11 6.58 ± 2.91 9.98 ± 3.98 9.36 ± 2.54 7.25 ± 2.73
s’ velocity (cm/sec) 6.40 ± 2.91 7.05 ± 2.18 5.83 ± 2.27 7.39 ± 3.56 7.15 ± 2.40 6.42 ± 4.67
E/e’ ratio 20.5 ± 12.8 14.7 ± 8.6 24.5 ± 13.9 14.2 ± 9.2 13.3 ± 8.7 21.1 ± 9.6
TR Vmax (m/sec) 3.7 ± 0.3 3.8 ± 0.5 3.7 ± 0.3 3.7 ± 0.4 3.8 ± 0.4 3.7 ± 0.3
PASP (mmHg) 65.5 ± 11.9 72.3 ± 18.1 62.3 ± 9.3 64.9 ± 10.8 65.6 ± 14.0 63.3 ± 7.9
Follow-up duration 32.4 (16.2–57.8) 43.7 (25.3– 34.6 (18.7–60.6) 17.7 (2.2–38.7) 29.0 (10.1–52.5) 29.5 (16.0–52.1)
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mean age of total study population was 67.7 ± 14.9 years,
and 51.4% were female. Patients of group I were younger
than other groups, and patients of group III were older
than other groups. More than two-thirds of patients
were female in group I and group IV, whereas more than
two-thirds were male in group III. Prevalence of comor-
bidities showed significant differences between the
WHO groups of PH: group II had a higher prevalence of
hypertension and dyslipidemia, and most of the group V
had chronic kidney disease (CKD) or end-stage renal
disease (ESRD).
Among the 333 patients with group I PH, 145 patients
(43.5%) underwent cardiac catheterization for confirma-
tive diagnosis of PAH in Seoul National University Bun-
dang Hospital and Seoul National University Hospital
during the study period. There were 177 patients
(53.2%) who were on any PAH-targeted therapy among
the group I PH patients: 132 patients (39.6%) were on
endothelin receptor antagonists, 88 patients (26.4%)
were on prostacyclin analogues, and 110 (33.0%) patients
were on phosphodiesterase type 5 inhibitors.
Echocardiographic parameters
Mean TR velocity of total study population was 3.7 ± 0.3
m/sec, and did not differ between the five subgroups
(Table 1). LVEF was markedly decreased in group II
(PH-LHD; 47.7 ± 16.3%), and was higher in group IV
(CTEPH; 61.4 ± 8.6%) and group I (PAH; 60.8 ± 8.4%).
LV cavity size and LV mass index were larger in groups
II and V than other groups, suggesting a more advanced
LV remodeling. Parameters of LV diastolic function,
such as LA volume index and LV filling pressure
assessed by E/e’ ratio, also showed worse results in these
subgroups.
Risk of mortality according to the PH subgroups
During 32.4 (IQR, 16.2–57.8) months of follow-up, 749
(34.3%) deaths were observed (Table 1). We compared
the all-cause mortality-free survival between the five
diagnostic subgroups, adjusting the survival curves with
the significant predictors for all-cause mortality (Fig. 1a).
Group II had a better prognosis than other groups, while
the risk of mortality was comparable between groups I,
IV, and V. The mortality risk was significantly higher in
group III than other groups.
The risk of all-cause mortality was also compared ac-
cording to the etiology of PAH in the group I PH pa-
tients (Fig. 1b). Patients with PAH associated with
connective tissue disease had the worst prognosis,
followed by those with idiopathic PAH. Those with con-
genital shunt had relatively benign clinical course.
Risk factors for mortality and different prognostic profiles
between PH subgroups
Given the significant differences in clinical characteristics
and prognosis across the subgroups of PH, we performed
Cox proportional hazard regression analysis models with
backward selection method in total study population as
well as in each PH subgroup. In total study population,
the multivariable analyses showed that, advanced age (ad-
justed HR, 1.875; 95% CI, 1.390–2.529; P < 0.001 for age >
70 years) and male sex (adjusted HR, 1.674; 95% CI,
1.262–2.220; P < 0.001) were associated with increased risk
of all-cause mortality (Table 2 and Additional file 2). A
lower hemoglobin level was associated with a higher mor-
tality risk (adjusted HR, 1.072; 95% CI, 1.010–1.138; P =
0.023 per − 1 g/dL of hemoglobin) (Additional file 3). The
risk of mortality was proportional to the severity of PH in
total study population, when stratified by PASP values of
60 and 70mmHg (Fig. 2), or the median value of 62
mmHg (adjusted HR, 1.559; 95% CI, 1.188–2.047; P <
0.001) (Table 2). Of note, the elevated PASP was associ-
ated with overall increase in the risk of mortality in most
subgroups (group I, II, III, and V; Fig. 2 and Table 2).
Risk factors for mortality showed differences between
the PH subgroups (Table 2). In group I PH, advanced
age, lower hemoglobin level, and elevated PASP were as-
sociated with higher mortality risk, and renal dysfunc-
tion showed a modest association with the mortality
risk. In group II PH, advanced age, male sex, lower
hemoglobin level, dilated LV cavity, and impaired LV
systolic function appeared to be significant risk factors,
Table 1 Baseline characteristics (Continued)
Total study
population








(n = 2185) (n = 333) (n = 1189) (n = 335) (n = 102) (n = 226)
(months) 64.0)
All-cause death 749 (34.3%) 92 (27.6%) 344 (28.9%) 192 (57.3%) 38 (37.3%) 83 (36.7%)
Data are shown as numbers (%), mean (±standard deviation), or median (interquartile ranges; Q1-Q3)
Abbreviations: PAH Pulmonary arterial hypertension, PH-LHD Pulmonary hypertension due to left heart disease, PH-Lung Pulmonary hypertension due to lung
disease or hypoxia, CTEPH Chronic thromboembolic pulmonary hypertension, PH-Miscellaneous Pulmonary hypertension with multifactorial mechanisms, BMI Body-
mass index, CKD Chronic kidney disease, HDL High-density lipoprotein, LDL Low-density lipoprotein, BUN Blood urea nitrogen, GFR Glomerular filtration rate,
HbA1c Hemoglobin A1c, LVEDD Left ventricular end-diastolic dimension, LVESD Left ventricular end-systolic dimension, LVEDV Left ventricular end-diastolic
volume, LVESV Left ventricular end-systolic volume, LVEF Left ventricular ejection fraction, LVMI Left ventricular mass index, LA Left atrium, LAVI Left atrial volume
index, TDI Tissue Doppler imaging, TR Tricuspid regurgitation, PASP Pulmonary artery systolic pressure
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while higher BMI was associated with low mortality risk.
In group III PH, a lower level of hemoglobin was associ-
ated with higher mortality, whereas the presence of
HTN was associated with lower mortality risk. Signifi-
cant variables associated with mortality were lower
hemoglobin level in group IV, and were advanced age
and male sex in group V.
Medical expenditure and healthcare utilization
During the follow-up period, there were 6692 events of
hospitalizations with 54,602 days of hospital stay and 52,
735 OPD visits among the total study population. The
annual number of hospitalizations and duration of hos-
pital stay were significantly higher in group V and group
II than other groups (Fig. 3a and Table 3). There was a
Fig. 1 Risk-adjusted survival curves of the PH subgroups. a All-cause mortality-free survival by the five diagnostic subgroups of PH by WHO
classification. b Risk-adjusted survival curves according to the etiologies of PAH. Abbreviations: PH, pulmonary hypertension; PAH, pulmonary
arterial hypertension; LHD, left heart disease; CTEPH, chronic thromboembolic pulmonary hypertension; HR, hazard ratio; CI, confidence interval
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tendency for a longer hospitalization among those with
higher PASP in groups I, II, and V (Fig. 3b).
The annual medical expenditure was 3531 $USD/per-
son-year (IQR, 949–10,708) in total study population,
and showed significant difference across the subgroups
of PH: the total cost per year was significantly larger in
group V, followed by group II (Fig. 3c and Table 3). Pa-
tients with higher PASP had more medical expenditure
than those with lower PASP in most subgroups of PH
(Fig. 3d).
Discussion
We identified patients with PH among those referred for
echocardiography, and categorized the patients accord-
ing to the WHO classification. The five diagnostic sub-
groups of PH demonstrated different clinical
characteristics and prognosis. Risk factors for mortality
were different between the subgroups; however, the se-
verity of PH was associated with higher risk of mortality
in most subgroups. Medical expenditure and healthcare
utilization were also different between the subgroups,
but tended to be proportional to the PH severity.
Different clinical features and prognosis between PH
subgroups
Group I (PAH) patients were younger females, and had
less traditional coronary risk factors compared to other
PH groups, as reported in previous studies [6]. In this
subgroup, major risk factors for mortality were age,
lower hemoglobin level, renal dysfunction and the sever-
ity of PH, whereas traditional coronary risk factors and
LV function parameters were not associated with mor-
tality risk. It has been suggested that the major deter-
minant of clinical deterioration in group I PH is the
increase in pulmonary artery pressure through vascular
remodeling, and this process is related with anemia and
renal dysfunction [9–11]. Better outcomes were ob-
served in PAH with congenital shunt, and worse out-
comes in those with connective tissue disease or
idiopathic PAH. These findings are similar to the previ-
ous studies, [4, 12] and suggest the importance of under-
lying pathophysiology.
Group II PH (PH-LHD) was characterized with im-
paired LV systolic and/or diastolic function [13]. Typical
features of HF, such as depressed LVEF and dilated LV
cavity, showed associations with mortality in this sub-
group. Presence of PH was an independent prognostic
factor for mortality, which was also observed in previous
studies [14]. The association between the low BMI and
low mortality risk support the obesity paradox in HF
[15].
In group III PH (PH-Lung), the risk factors for all-
cause mortality were age, lower level of hemoglobin, and
the severity of PH, whereas the presence of HTN was as-
sociated with a lower mortality risk. Indeed, anemia is
prevalent in patients with chronic obstructive pulmonary
disease (COPD) by multi-factorial pathogenesis, includ-
ing chronic inflammation, nutritional deficits, stress
Fig. 2 Severity of PH and all-cause mortality. Risk-adjusted all-cause mortality-free survival curves are shown, according to the severity of PH in (a)
total study population, (b) group I PAH, (c) group II PH-LHD, (d) group III PH-Lung, (e) group IV CTEPH, and (f) group V PH-Miscellaneous
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ulcer, and effects of cigarette smoking [16, 17]. The pres-
ence of anemia is associated with increased mortality
risk, and notably, may contribute to the development
and progression of PH in COPD patients through hyp-
oxic pulmonary vasoconstriction [18]. Our findings sup-
port that lower hemoglobin level and elevated PASP
may reflect a more advanced stage of PH-Lung, which is
associated with an increased risk of all-cause mortality
[19, 20]. Of note, the risk of all-cause mortality was the
highest in the group III, and lowest in the group II,
among the PH subgroups, in concordance with the re-
sults from the ASPIRE (Assessing the Spectrum of Pul-
monary hypertension Identified at a REferral centre)
registry, where the 5-year survival rates were less than
40% among the group III PH patients, about 50% among
the group I PH patients, and higher than 60% among the
group II PH patients [4]. However, according to the
Armadale cohort, the risk of mortality was similar
between the patients with PH-LHD (group II) and PH-
Lung (group III), whereas lower in PAH (group I) [2].
These differences may be attributable to the severity of
PH of each study: the Armadale cohort included the pa-
tients with mild PH (inclusion criteria, PASP > 40
mmHg; mean PASP, 56 mmHg), whereas we mainly en-
rolled those with moderate or severe PH (inclusion cri-
teria, peak TR velocity > 3.4 m/sec; mean PASP, 66
mmHg).
The significant difference in prognosis between PH-
LHD and PH-Lung, despite the similar severity of PH,
reflects the different etiology for development and pro-
gression of PH in each subgroup. In patients with HF,
diastolic dysfunction leads to passive backward transmis-
sion of LV filling pressures, and some of these patients
develop further increment in pulmonary artery pressure
through pulmonary vasoconstriction, decreased nitric
oxide availability, increased endothelin expression, and
Fig. 3 Healthcare utilization and medical expenditure across the subgroups of PH. Durations of hospital stay per person-year according to the (a)
PH subgroups, and (b) severity of PH among the subgroups. Total medical expenditure per person-year was also compared according to the (c)
PH subgroups, and (d) severity of PH among the subgroups. Patients with follow-up duration < 6months were excluded from this analysis
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vascular remodeling [21, 22]. Given the elevated LV end-
diastolic pressure (LVEDP) as the main pathophysiology in
PH-LHD, there is a room for alleviation of the increased
LV filling pressure and PH through intravascular volume
reduction, as suggested in previous studies with findings of
the exaggerated relationship between volume overload and
the increase in LVEDP and PAP in HF patients [9, 10]. In
contrast, PH in chronic lung disease is attributable to the fi-
brotic injuries including neomuscularization, intimal thick-
ening, and medial hypertrophy through chronic hypoxia,
cigarette smoking, and airway and vascular wall inflamma-
tion [21]. Because of these irreversible structural changes,
the presence of PH indicates far-advanced stage of pulmon-
ary vascular remodeling. Indeed, the prevalence of PH is
approximately 90% in stage IV COPD, and 5-year survival
rate of patients with COPD and PH is only 36% [19, 23].
Therefore, the differences in pathophysiology between the
group II and group III PH seem to be the main reason for
the different prognosis.
In our study, most of the patients in group V (PH-Mis-
cellaneous) had CKD/ESRD. It would be attributable to
the study design: the study population was identified from
tertiary referral centers, and the patients with prior or
current malignancies were excluded. According to the
previous studies, the prevalence of PH has been reported
to range from 10 to 30% in CKD/ESRD patients [24]. De-
velopment of PH in these patients is explained by in-
creased cardiac output, anemia, uremic physiology,
vascular calcification, and recurrent subclinical thrombo-
embolic events [24]. Of note, there is a debate regarding
the elevated LVEDP as a potential cause of PH in CKD/
ESRD. Considering that patients with CKD/ESRD and PH
usually have elevated LV filling pressure, it can be argued
that some of these patients could have been classified as
group II (PH-LHD) [24, 25]. Although the patients with
≥grade II diastolic dysfunction were categorized into PH-
LHD regardless of the presence of CKD/ESRD in the
present study, the overall echocardiographic parameters of








LHD) (n = 1189)
Group III (PH-








Number of hospitalizations 1 (0–4) 2 (0–4) 1 (0–4) 1 (0–3) 1 (0–2) 2 (1–6)
Total duration of hospitalization
(days)
9 (0–29) 9 (0–27) 10 (0–30) 4 (0–24) 2 (0–13) 9 (1–42)
Number of OPD visits 15 (4–34) 22 (9–43) 15 (6–33) 7 (1–23) 12 (2–27) 19 (5–43)
Annualized rates of healthcare utilization
Number of hospitalizations per
year (events/person-year)
0.4 (0.0–1.2) 0.4 (0.0–1.1) 0.4 (0.0–1.2) 0.3 (0.0–1.1) 0.2 (0.0–0.6) 0.7 (0.2–1.6)
Duration of hospitalization per
year (days/person-year)
2.3 (0.0–8.2) 2.2 (0.0–6.8) 2.7 (0.0–8.3) 1.4 (0.0–8.9) 0.5 (0.0–4.9) 3.1 (0.4–10.9)
Number of OPD visits per year
(visits/person-year)
4.6 (1.4–9.4) 5.5 (2.6–10.0) 4.6 (1.7–9.2) 2.5 (0.4–8.2) 4.0 (0.8–8.4) 6.0 (1.8–12.1)
Medical expenditurea




















Cost for medications ($USD) 422 (129–1272) 598 (176–
1935)
409 (123–1187) 296 (119–823) 283 (93–950) 493 (155–1868)
Annual medical expenditure
Total costs per year ($USD/
person-year)









Cost for testing per year ($USD/
person-year)
1135 (452–2492) 1017 (488–
2072)
1196 (440–2490) 1070 (393–2397) 785 (366–1735) 1573 (594–3183)
Cost for medications per year
($USD/person-year)
110 (34–372) 140 (42–479) 105 (31–348) 95 (35–298) 81 (25–238) 139 (43–690)
Data are shown as median (interquartile ranges; Q1-Q3)
aMedical costs were assessed in Korean Won (KRW), and were translated into US dollars ($USD) using a currency exchange rate of 1123 KRW/$USD
Healthcare utilization was compared between the PH subgroups using the number of hospitalization, total duration of hospital stay, and number of outpatient
department (OPD) visits. Medical expenditure was compared using the total medical costs, cost for testing, and cost for medications. The outcome parameters
were annualized and averaged within each PH subgroup
Abbreviations: same as Table 1
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group V were similar to those in group II. Our findings
suggest that diastolic dysfunction maybe an important fac-
tor for development of PH in CKD/ESRD, and that the
differential categorization between group II and group V
can be difficult as those groups share similar pathophysi-
ology. Although the group II PH patients and the group V
PH patients with CKD/ESRD have similar characteristics
of volume overload and LV diastolic dysfunction, the
healthcare utilization and medical expenditure were larger
in group V patients than in group II patients. These find-
ings may be attributable to the additional medications for
renal dysfunction and more hospital visits for dialysis in
the group V patients with CKD/ESRD.
PH as a marker of “patient-burden”
The annual medical expenditure was the largest in group
V, followed by group II. Frequency of healthcare
utilization showed similar results. Our findings suggest
that different patterns of healthcare utilization and med-
ical expenditure may originate from the differences in
pathophysiology and clinical consequences. Although pa-
tients with PAH are recognized as consuming the highest
medical expenditure, we showed that medical expenditure
in group V PH can be larger than those of group I PH. It
might be attributable to the following factors: (1) about
70% of the group I patients had ever received PAH-
specific medications as a clinical trial and could not be
identified from reimbursement data; (2) the prescription
of PAH-specific drugs was under strict criteria for insur-
ance coverage; and (3) most of group V patients had
ESRD, which requires large medical expenditures.
In usual clinical situation, the presence of PH and its
severity can be recognized as a secondary finding to a
specific pathophysiology attributable to the development
and progression of PH. However, we demonstrated that
the severity of PH per se may affect the mortality risk as
well as the healthcare utilization and medical expend-
iture regardless of the WHO classification. Therefore,
the presence and severity of PH should also be recog-
nized with sufficient clinical vigilance.
Limitations
First, the presence of PH was determined by echocardi-
ography rather than cardiac catheterization. Therefore,
we could not provide invasive measurements of the pul-
monary artery pressure and the differentiation between
pre-capillary and post-capillary PH. Given the lack of
cardiac catheterization data, we tried to improve the spe-
cificity for the diagnosis of PH using a high cutoff value
of TR Vmax. According to the clinical guidelines, pa-
tients with a TR Vmax > 3.4 m/sec are highly suggestive
of PH and do not require any further echocardiographic
signs for the diagnosis of PH [3]. This inclusion criterion
would have contributed to the exclusion of patients with
transient elevation of PASP from other causes rather
than true PH. Although the diagnosis of PH of our study
can be inaccurate in some patients, the overall results
would not be changed because the cutoff value of TR
velocity (3.4 m/sec) was high enough to select the pa-
tients with PH [3]. Second, we could not provide the
symptomatic status due to the incomplete medical re-
cords. Given the well-established prognostic value of
symptomatic status in PH patients, the interpretation of
our findings needs caution. Third, we compared the clin-
ical characteristics and the profiles of risk factors for
mortality between the PH subgroups, except for group
IV PH in which the sample size was not large enough.
Fourth, most of the group V PH patients had CKD/
ESRD, and there were few patients with other diseases.
However, we think the distribution of WHO groups of
our study can reflect the real-world practice.
Conclusions
The five diagnostic subgroups of PH by the WHO classi-
fication had significantly different clinical characteristics,
echocardiographic findings, and the risk of mortality.
The profiles of risk factors for mortality were different
according to the etiology of PH, while the elevated PASP
was associated with higher mortality risk in most sub-
groups. Medical expenditure and healthcare utilization
were also different between the PH subgroups, but
tended to be proportional to the severity of PH. Our
findings implicate the importance of comprehensive un-
derstanding of the PH in each subgroup.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12890-019-0945-0.
Additional file 1: Diagnostic codes for classification of PH subgroups. A
table of diagnostic codes for the classification of PH subgroups.
Additional file 2: Univariable Cox proportional hazard regression
analysis. A table of results of univariable Cox proportional hazard
regression analyses for the occurrence of all-cause mortality in total study
population.
Additional file 3: Relationship between the hemoglobin levels and the
risk of all-cause mortality. A spline curve showing the relationship be-
tween the levels of hemoglobin and the risk of all-cause mortality in total
study population.
Abbreviations
CKD: Chronic kidney disease; CTEPH: Chronic thromboembolic pulmonary
hypertension; ESRD: End-stage renal disease; LVEF: Left ventricular ejection
fraction; PAH: Pulmonary arterial hypertension; PAP: Pulmonary artery
pressure; PASP: Pulmonary artery systolic pressure; PH: Pulmonary
hypertension; PH-LHD: Pulmonary hypertension due to left-sided heart dis-
ease; PH-Lung: Pulmonary hypertension due to lung disease or hypoxia; PH-
Miscellaneous: Pulmonary hypertension with multifactorial mechanisms;
TR: Tricuspid regurgitation; WHO: World Health Organization
Acknowledgements
None.
Hwang et al. BMC Pulmonary Medicine          (2019) 19:189 Page 10 of 11
Authors’ contributions
Research idea and study design: ICH, GYC; data acquisition: ICH, GYC, HMC,
YEY, JJP, JBP, SPL, HKK, YJK, DWS; data analysis and interpretation: ICH, GYC,
HMC; statistical analysis: ICH, GYC; supervision and mentorship: GYC. Each
author contributed important intellectual content for writing the manuscript
and accepts accountability for the overall work by confirming that questions
pertaining to the accuracy or integrity of any portion of the work have been
appropriately investigated and resolved. GYC confirms that this study has
been reported honestly, accurately, and transparently. All authors read and




This study was supported by Seoul National University Bundang Hospital
(13–2016-018).
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study was carried out according to the principles of the Declaration of
Helsinki and approved by the Clinical Research Institute of Seoul National




The authors declare that they have no competing interests.
Author details
1Department of Cardiology, Cardiovascular Center, Seoul National University
Bundang Hospital, Seongnam, Gyeonggi, South Korea. 2Department of
Internal Medicine, Seoul National University College of Medicine, Seoul,
South Korea. 3Division of Cardiology, Hallym Sacred Heart Hospital, Hallym
University College of Medicine, Anyang, South Korea. 4Cardiovascular Center
and Department of Internal Medicine, Seoul National University Hospital,
Seoul, South Korea.
Received: 9 February 2019 Accepted: 20 September 2019
References
1. Moreira EM, Gall H, Leening MJ, Lahousse L, Loth DW, Krijthe BP, et al.
Prevalence of pulmonary hypertension in the general population: the
Rotterdam study. PLoS One. 2015;10(6):e0130072.
2. Strange G, Playford D, Stewart S, Deague JA, Nelson H, Kent A, et al.
Pulmonary hypertension: prevalence and mortality in the Armadale
echocardiography cohort. Heart. 2012;98(24):1805–11.
3. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/
ERS guidelines for the diagnosis and treatment of pulmonary hypertension:
the joint task force for the diagnosis and treatment of pulmonary
hypertension of the European Society of Cardiology (ESC) and the European
Respiratory Society (ERS): endorsed by: Association for European Paediatric
and Congenital Cardiology (AEPC), International Society for Heart and Lung
Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.
4. Hurdman J, Condliffe R, Elliot CA, Davies C, Hill C, Wild JM, et al. ASPIRE
registry: assessing the Spectrum of pulmonary hypertension identified at a
REferral Centre. Eur Respir J. 2012;39(4):945–55.
5. Chang WT, Weng SF, Hsu CH, Shih JY, Wang JJ, Wu CY, et al. Prognostic
factors in patients with pulmonary hypertension-a Nationwide cohort study.
J Am Heart Assoc. 2016;5(9):e003579.
6. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al.
Pulmonary arterial hypertension: baseline characteristics from the REVEAL
registry. Chest. 2010;137(2):376–87.
7. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen
T, et al. Recommendations for the evaluation of left ventricular diastolic
function by echocardiography: an update from the American Society of
Echocardiography and the European Association of Cardiovascular Imaging.
J Am Soc Echocardiogr. 2016;29(4):277–314.
8. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al.
Recommendations for cardiac chamber quantification by echocardiography
in adults: an update from the American Society of Echocardiography and
the European Association of Cardiovascular Imaging. J Am Soc
Echocardiogr. 2015;28(1):1–39 e14.
9. Robinson JC, Graham BB, Rouault TC, Tuder RM. The crossroads of iron with
hypoxia and cellular metabolism. Implications in the pathobiology of
pulmonary hypertension. Am J Respir Cell Mol Biol. 2014;51(6):721–9.
10. Haddad F, Fuh E, Peterson T, Skhiri M, Kudelko KT, De Jesus PV, et al.
Incidence, correlates, and consequences of acute kidney injury in patients
with pulmonary arterial hypertension hospitalized with acute right-side
heart failure. J Card Fail. 2011;17(7):533–9.
11. Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M.
Association of serum creatinine with abnormal hemodynamics and
mortality in pulmonary arterial hypertension. Circulation. 2008;117(19):
2475–83.
12. Escribano-Subias P, Blanco I, Lopez-Meseguer M, Lopez-Guarch CJ, Roman
A, Morales P, et al. Survival in pulmonary hypertension in Spain: insights
from the Spanish registry. Eur Respir J. 2012;40(3):596–603.
13. Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease.
Circulation. 2012;126(8):975–90.
14. Dzudie A, Kengne AP, Thienemann F, Sliwa K. Predictors of hospitalisations
for heart failure and mortality in patients with pulmonary hypertension
associated with left heart disease: a systematic review. BMJ Open. 2014;4(7):
e004843.
15. Nagarajan V, Kohan L, Holland E, Keeley EC, Mazimba S. Obesity paradox in
heart failure: a heavy matter. ESC Heart Fail. 2016;3(4):227–34.
16. John M, Hoernig S, Doehner W, Okonko DD, Witt C, Anker SD. Anemia and
inflammation in COPD. Chest. 2005;127(3):825–9.
17. Yohannes AM, Ershler WB. Anemia in COPD: a systematic review of the
prevalence, quality of life, and mortality. Respir Care. 2011;56(5):644–52.
18. Plesner LL, Schoos MM, Dalsgaard M, Goetze JP, Kjoller E, Vestbo J, et al.
Iron deficiency in COPD associates with increased pulmonary artery
pressure estimated by echocardiography. Heart Lung Circ. 2017;26(1):101–4.
19. Andersen KH, Iversen M, Kjaergaard J, Mortensen J, Nielsen-Kudsk JE,
Bendstrup E, et al. Prevalence, predictors, and survival in pulmonary
hypertension related to end-stage chronic obstructive pulmonary disease. J
Heart Lung Transplant. 2012;31(4):373–80.
20. Wrobel JP, Thompson BR, Williams TJ. Mechanisms of pulmonary
hypertension in chronic obstructive pulmonary disease: a pathophysiologic
review. J Heart Lung Transplant. 2012;31(6):557–64.
21. Singh I, Ma KC, Berlin DA. Pathophysiology of pulmonary hypertension in
chronic parenchymal lung disease. Am J Med. 2016;129(4):366–71.
22. Hwang IC, Kim YJ, Park JB, Yoon YE, Lee SP, Kim HK, et al. Pulmonary
hemodynamics and effects of phosphodiesterase type 5 inhibition in heart
failure: a meta-analysis of randomized trials. BMC Cardiovasc Disord. 2017;
17(1):150.
23. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A,
Charpentier C, et al. Prognostic factors in COPD patients receiving long-
term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995;
107(5):1193–8.
24. Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients
with chronic and end-stage kidney disease. Kidney Int. 2013;84(4):682–92.
25. Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Grohe C, Nickenig G, et al.
Pulmonary hypertension in patients with chronic kidney disease on dialysis
and without dialysis: results of the PEPPER-study. PLoS One. 2012;7(4):
e35310.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Hwang et al. BMC Pulmonary Medicine          (2019) 19:189 Page 11 of 11
